Physician profile
Keith Steinbecker
NPI 1992763197
$9,510.44
in general payments reported to CMS, 2019-2025
63 companies · $1,847 in 2025
The $1,847 reported for 2025 was more than what 78% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,308 · 2020: $273 · 2021: $1,230 · 2022: $1,404 · 2023: $1,813 · 2024: $1,636 · 2025: $1,847.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,938 · Travel and Lodging: $358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,938.11 |
| Travel and Lodging | $357.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,049.96 | 2019-2025 | Myrbetriq, Xtandi |
| Abbvie INC. | $882.77 | 2019-2025 | Botox, Lupron Depot |
| Myriad Genetic Laboratories, INC. | $633.08 | 2021-2025 | Prolaris |
| Sumitomo Pharma America, INC. | $600.48 | 2023-2025 | Gemtesa, Orgovyx |
| Boston Scientific Corporation | $580.40 | 2019-2025 | General - Kidney Stone Disease, Lithovue, Ams 700 Cxr Rte Kit |
| Procept Biorobotics Corporation | $457.89 | 2022-2023 | Aquabeam Robotic System |
| Allergan, INC. | $312.30 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $286.24 | 2021-2025 | Keytruda, Welireg, Lynparza |
| Becton, Dickinson and Company | $276.33 | 2024 | Bard Urinary Drainage Bag |
| Janssen Biotech, INC. | $267.94 | 2019-2025 | Erleada, Akeega, Balversa |
| C. R. Bard, INC. & Subsidiaries | $249.27 | 2019-2025 | Bard Urinary Drainage Bag |
| Rochester Medical Corporation | $240.00 | 2020-2022 | |
| Agiliti Health, INC. | $234.07 | 2024-2025 | Sonablate Hifu, Koelis Trinity Mri/US Fusion |
| Urogen Pharma, INC. | $233.14 | 2022-2025 | Jelmyto |
| Ferring Pharmaceuticals INC. | $203.37 | 2019-2025 | Adstiladrin |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Steinbecker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.